AFP and hepatocellular carcinoma: AFP-L3 is a glycoprotein, which contains α-1,6-fucose attached to N-acetylglucosamine at its reducing terminus, while AFP-L3 aberrant fucosylation is used in identifying HCV, chronic hepatitis B (CHB), and liver cirrhosis (LC) patients with high risk of HCC development.